Suven Pharma posted strong numbers in the last quarter led by re-initiation of supplies in the CRAMS space. EBITDA margin was at 50 percent which is way higher than peers such as Syngene, Gland Pharma, and Divis Lab.

In the special segment ‘Moneycontrol Pro Ideas For Profit’, moneycontrol.com’s Anubhav Sahu gets more details on how the company is expected to perform going forward.

Watch the video for more.

(Edited by : Abhishek Jha)